Human facilitating cells
US-9452184-B2 · Sep 27, 2016 · US
US10160953B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10160953-B2 |
| Application number | US-201514886577-A |
| Country | US |
| Kind code | B2 |
| Filing date | Oct 19, 2015 |
| Priority date | Apr 23, 2009 |
| Publication date | Dec 25, 2018 |
| Grant date | Dec 25, 2018 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
The invention provides a nutrient medium composition and associated methods for lengthening the useful life of a culture of muscle cells. Disclosed is a method of culturing mammalian muscle cells, including preparing one or more carriers coated with a covalently bonded monolayer of trimethoxy-silylpropyl-diethylenetriamine (DETA); verifying DETA monolayer formation by one or more associated optical parameters; suspending isolated fetal rat skeletal muscle cells in serum-free medium according to medium composition 1; plating the suspended cells onto the prepared carriers at a predetermined density; leaving the carriers undisturbed for cells to adhere to the DETA monolayer; covering the carriers with a mixture of medium 1 and medium 2; and incubating. A cell nutrient medium composition includes Neurobasal, an antibiotic-antimycotic composition, cholesterol, human TNF-alpha, PDGF BB, vasoactive intestinal peptides, insulin-like growth factor 1, NAP, r-Apolipoprotein E2, purified mouse Laminin, beta amyloid, human tenascin-C protein, rr-Sonic hedgehog Shh N-terminal, and rr-Agrin C terminal.
Opening claim text (preview).
That which is claimed: 1. A method of maintaining a muscle cell culture, the method comprising: maintaining the muscle cell culture in a serum-free maintenance medium comprising the components at the concentrations listed in Table 3, the components at the concentrations listed in Table 4, the components at the concentrations listed in Table 5, creatine, estrogen, and cholesterol wherein the cells in the muscle cell culture consist of muscle cells. 2. The method of claim 1 , wherein the muscle cell culture is maintained in the serum-free maintenance medium for at least 30 days. 3. The method of claim 2 , wherein the muscle cell culture is maintained in the serum-free maintenance medium for at least 50 days. 4. The method of claim 1 , further comprising plating the muscle cell culture onto a non-biological growth substrate prior to maintaining the muscle cell culture in the serum-free maintenance medium. 5. The method of claim 4 , wherein the non-biological growth substrate comprises a silane molecule. 6. The method of claim 5 , wherein the non-biological growth substrate is trimethoxy-silylpropyl-diethylenetriamine (DETA). 7. The method of claim 1 , further comprising plating the muscle cell culture at a density of 700 to 1000 muscle cells per square millimeter prior to maintaining the muscle cell culture in the serum-free maintenance medium. 8. The method of claim 1 , further comprising replenishing the serum-free maintenance medium every 1 to 5 days. 9. The method of claim 8 , further comprising replenishing the serum-free maintenance medium every 3 days. 10. The method of claim 1 , further comprising incubating the muscle cell culture in a first serum-free medium prior to maintaining the muscle cell culture in the serum-free maintenance medium. 11. The method of claim 10 , wherein the first serum-free medium comprises a factor selected from the group consisting of vascular endothelial growth factor (VEGF), acidic fibroblast growth factor (FGF), heparin sulfate, leukemia inhibitory factor (LIF), vitronectin, ciliary neurotrophic factor (CNTF), neurotrophin-3 (NT-3), neurotrophin-4 (NT-4), glial cell-derived neurotrophic factor (GDNF), brain-derived neurotrophic factor (BDNF), cardiotrophin-1 (CT-1), cholesterol, tumor necrosis factor alpha (TNF-alpha), platelet derived growth factor (PDGF), vasoactive intestinal peptide, insulin-like growth factor 1, neutrophil activating protein (NAP), r-Apolipoprotein, laminin, beta amyloid, tenascin-C protein, rr-sonic hedgehog, and rr-agrin. 12. The method of claim 11 , wherein the first serum-free medium comprises vitronectin. 13. The method of claim 12 , wherein the first serum-free medium is a mixture of approximately equal volumes of the medium composition of Table 1 and the medium composition of Table 2. 14. The method of claim 10 , wherein the muscle cell culture is maintained in the first serum-free medium from 2 to 6 days. 15. The method of claim 14 , wherein the muscle cell culture is maintained in the first serum-free medium for 4 days.
Synthetic polymers · CPC title
Cells of skeletal and connective tissues; Mesenchyme · CPC title
Skeletal muscle cells, myocytes, myoblasts, myotubes · CPC title
Skeletal muscle cells, e.g. myocytes, myotubes, myoblasts · CPC title
Regulators of development · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.